SCI Pharmtech Inc Asset Resilience Ratio
SCI Pharmtech Inc asset resilience ratio. SCI Pharmtech Inc (4119) has an Asset Resilience Ratio of 0.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of SCI Pharmtech Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SCI Pharmtech Inc (2003–2025)
Asset resilience ratio of SCI Pharmtech Inc from 2003 to 2025. This chart shows how SCI Pharmtech Inc's Asset Resilience Ratio has changed over time. See SCI Pharmtech Inc (4119) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down SCI Pharmtech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 4119 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.01 Million | 0.01% |
| Total Liquid Assets | NT$1.01 Million | 0.01% |
Asset Resilience Insights
- Limited Liquidity: SCI Pharmtech Inc maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SCI Pharmtech Inc Industry Peers by Asset Resilience Ratio
Compare SCI Pharmtech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
SCI Pharmtech Inc Asset Resilience Ratio by Year (2003–2025)
SCI Pharmtech Inc asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for SCI Pharmtech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.21% | NT$14.17 Million ≈ $446.46K |
NT$6.89 Billion ≈ $216.97 Million |
-1.33pp |
| 2024-12-31 | 1.53% | NT$110.37 Million ≈ $3.48 Million |
NT$7.20 Billion ≈ $226.86 Million |
+0.20pp |
| 2023-12-31 | 1.33% | NT$89.00 Million ≈ $2.80 Million |
NT$6.69 Billion ≈ $210.80 Million |
-0.64pp |
| 2022-12-31 | 1.97% | NT$97.55 Million ≈ $3.07 Million |
NT$4.96 Billion ≈ $156.28 Million |
-6.64pp |
| 2021-12-31 | 8.60% | NT$360.40 Million ≈ $11.35 Million |
NT$4.19 Billion ≈ $132.00 Million |
-2.82pp |
| 2019-12-31 | 11.42% | NT$466.02 Million ≈ $14.68 Million |
NT$4.08 Billion ≈ $128.59 Million |
+0.07pp |
| 2018-12-31 | 11.35% | NT$430.11 Million ≈ $13.55 Million |
NT$3.79 Billion ≈ $119.38 Million |
-1.23pp |
| 2017-12-31 | 12.58% | NT$414.74 Million ≈ $13.07 Million |
NT$3.30 Billion ≈ $103.83 Million |
-2.56pp |
| 2016-12-31 | 15.15% | NT$537.79 Million ≈ $16.94 Million |
NT$3.55 Billion ≈ $111.86 Million |
+2.66pp |
| 2015-12-31 | 12.49% | NT$431.66 Million ≈ $13.60 Million |
NT$3.46 Billion ≈ $108.92 Million |
+7.24pp |
| 2014-12-31 | 5.24% | NT$168.93 Million ≈ $5.32 Million |
NT$3.22 Billion ≈ $101.48 Million |
+2.78pp |
| 2013-12-31 | 2.47% | NT$75.32 Million ≈ $2.37 Million |
NT$3.05 Billion ≈ $96.17 Million |
+2.46pp |
| 2010-12-31 | 0.01% | NT$122.00K ≈ $3.84K |
NT$1.50 Billion ≈ $47.40 Million |
-0.06pp |
| 2009-12-31 | 0.06% | NT$813.00K ≈ $25.61K |
NT$1.25 Billion ≈ $39.45 Million |
-1.15pp |
| 2008-12-31 | 1.21% | NT$13.71 Million ≈ $431.81K |
NT$1.13 Billion ≈ $35.69 Million |
-12.04pp |
| 2004-12-31 | 13.25% | NT$118.70 Million ≈ $3.74 Million |
NT$896.13 Million ≈ $28.23 Million |
+6.31pp |
| 2003-12-31 | 6.93% | NT$59.18 Million ≈ $1.86 Million |
NT$853.62 Million ≈ $26.89 Million |
-- |
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more